51.82 +0.26 (0.50%)
Pre-Market: 4:44AM EDT
|Bid||51.43 x 900|
|Ask||51.92 x 800|
|Day's Range||51.32 - 51.90|
|52 Week Range||36.28 - 80.66|
|Beta (3Y Monthly)||1.89|
|PE Ratio (TTM)||61.75|
|Forward Dividend & Yield||0.84 (1.63%)|
|1y Target Est||N/A|
Today we will run through one way of estimating the intrinsic value of Perrigo Company plc (NYSE:PRGO) by taking the...
Five years in the making. That is essentially the time it has taken for the S&P 500 to hit a milestone mark at 3,000 for the first time in its history. The stock gauge first closed at 2,000 on Aug. 26, 2014, according to Dow Jones Market Data.
Perrigo Company PLC NYSE:PRGOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for PRGO with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 24. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.32 billion over the last one-month into ETFs that hold PRGO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Shares of Dublin-based Perrigo Co. Plc rose 1.5% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration had approved a development partner's marketing application for a generic version of Metrogel-Vaginal, a treatment for bacterial vaginosis. The generic was developed in partnership with Capstone Development Solutions, a unit of Water Street Healthcare Partners, and Perrigo will get full ownership of the application within the next 30 days. Annual market sales for Metrogel-Vaginal for the 12 months ending May 2019 were around $100 million, Perrigo said, and the company plans to start selling the drug immediately after getting ownership of the application. Shares of the company have gained 27.4% in the year to date through Tuesday, while the S&P 500 has gained 18.6%.
Perrigo Company (NYSE: PRGO ) has acquired Ranir Global Holdings, a supplier of oral self-care products for $750 million in cash. Perrigo also adjusted its FY2019 earnings guidance, from $3.75-$4.05 including ...
Shares of Perrigo Co. Plc rose 2% in premarket trade Tuesday after the company raised its adjusted full-year EPS guidance to between $3.75 and $4.05 from between $3.65 and $3.95. The Dublin-based pharmaceutical company said the 10-cent boost came from its $750 million cash acquisition of oral-care products company Ranir Global Holdings LLC, which Perrigo said had successfully closed. Shares of Perrigo have gained 25% in the year to date through Monday, while the S&P 500 has gained 18.3%.
Is Perrigo Company plc (NYSE:PRGO) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Dividend paying stocks like Perrigo Company plc (NYSE:PRGO) tend to be popular with investors, and for good reason...
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Every investor in Perrigo Company plc (NYSE:PRGO) should be aware of the most powerful shareholder groups. Large...
U.S. stocks fell on Wednesday, as a clutch of weak economic data from the United States and China sparked worries of slowing global growth against the backdrop of a bitter trade dispute that has roiled financial markets. Domestic data showed retail sales unexpectedly fell in April as households cut back on purchases of motor vehicles and a range of other goods, and another report showed declining output of cars and machinery led to a surprise fall in U.S. factory production for April. Meanwhile data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on the country to roll out more stimulus.
Wall Street was set to open lower on Wednesday, as a surprise fall in domestic retail sales and underwhelming data from China raised growth concerns, while investors waited for more developments on the U.S.-China trade dispute. Government data showed U.S. retail sales unexpectedly fell in April as motor vehicle purchases slumped, while data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on Beijing to roll out more stimulus. "The U.S. retail sales report is clearly disappointing.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
FEATURE The S&P 500 was getting hammered this morning amid continued trade fears. Many of the 500 stocks in the index were down Thursday morning, dragging the index down as low as 1.5%. But not every stock was losing.
Perrigo (PRGO) reports encouraging first-quarter 2019 results. The Rx segment recovers during the quarter on strong new product sales.
was gaining more than 5% Thursday after announcing the all-cash acquisition of privately-held Ranir Global Holdings in a deal valued at $750 million. Ranir is the largest private label oral care company in the world, according to Perrigo, with a portfolio of more than 300 oral care products including toothbrush heads and whitening strips. "The addition of Ranir to the Perrigo family illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories.
Perrigo Co. said Thursday that it has reached an agreement to acquire privately-held oral care company Ranir Global Holdings LLC in a $750 million all-cash deal, or $685 million including cash tax benefits. The announcement is part of a transformation strategy that the self-care company unveiled during its investor day event. Ranir's portfolio includes more than 300 oral care items including manual toothbrushes, floss and dentures. The deal is expected to be about 10 cents per share accretive to 2019 adjusted earnings based on a third-quarter closing. The move is part of Perrigo's strategy to grow in self-care adjacent areas of business, according to a statement from Chief Executive Murray Kessler. Ranir has 650 employees and generated $287 million in net sales in 2018. Annual operating synergies between the two companies are expected to be about $10 million by 2021. The company also reaffirmed its plans to sell or spin off the generic pharmaceuticals business by the end of 2019 or in 2020; divest the animal health business through a $185 million cash deal with PetIQ Inc. ; investing more than $250 million in incremental capital over the next four years to expand the infant nutrition and tablet manufacturing businesses; and launching a cost savings program that will generate $100 million in annualized cost savings. Perrigo is also in discussions with several cannabidiol (CBD) companies to create products, among other innovations the company is pursuing. For 2019, Perrigo is guiding for sales between $4.6 billion and $4.7 billion, EPS between $1.24 and $1.54, and adjusted EPS of $3.65 to $3.95. The FactSet consensus is for sales of $4.7 billion and EPS of $4.14. Perrigo shares are up 27% for the year to date while the S&P 500 index has gained nearly 15%.
Perrigo (PRGO) delivered earnings and revenue surprises of 13.83% and 2.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?